235 results on '"de Graeff, Pieter A."'
Search Results
2. Stand van zaken kleinschalige, passieve visserij in windparken op zee : Een bundeling van bestaande kennis en een verkenning naar de mogelijkheden voor kleinschalige, passieve visserij in windparken
3. Implications of a clinical medication review and a pharmaceutical care plan of polypharmacy patients with a cardiovascular disorder
4. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers
5. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
6. Patient beliefs about medicines and quality of life after a clinical medication review and follow-up by a pharmaceutical care plan: a study in elderly polypharmacy patients with a cardiovascular disorder
7. Understanding drug preferences, different perspectives
8. Post-Approval Safety Issues with Innovative Drugs: A European Cohort Study
9. The Additional Value of an E-Mail to Inform Healthcare Professionals of a Drug Safety Issue: A Randomized Controlled Trial in the Netherlands
10. Healthcare Professionals’ Self-Reported Experiences and Preferences Related to Direct Healthcare Professional Communications: A Survey Conducted in the Netherlands
11. Impact of Safety-Related Regulatory Action on Clinical Practice: A Systematic Review
12. Effect of Safety Issues with HIV Drugs on the Approval Process of Other Drugs in the Same Class: An Analysis of European Public Assessment Reports
13. Predictive Value Of Ambulatory Blood Pressure Shortly After Withdrawal Of Antihypertensive Drugs In Primary Care Patients
14. A Decade of Safety-Related Regulatory Action in the Netherlands: A Retrospective Analysis of Direct Healthcare Professional Communications from 1999 to 2009
15. Effect of First Myocardial Ischemic Event on Renal Function
16. Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
17. Patiënten in geneesmiddelenonderzoek verschillen van latere gebruikers
18. The Additional Value of an e-Mail to Inform Healthcare Professionals of a Drug Safety Issue: 501.
19. The Role of the thorough QT Study in Drug Development: 431.
20. Dronedarone in High-Risk Permanent Atrial Fibrillation
21. Additional safety risk to exceptionally approved drugs in Europe?
22. Regulatory pathways for development of antiarrhythmic drugs for management of atrial fibrillation/flutter†
23. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy
24. Alterations in the Prognosis of Chronic Heart Failure: An Overview of the Major Mortality Trials
25. Cardiovascular end-organ damage in Ren-2 transgenic rats compared to spontaneously hypertensive rats
26. A Drugʼs Life Cycle and Communication of Safety Issues: 468.
27. The 4S Study: Implications for Prescribing
28. Oral Contraceptives and the Absolute Risk of Venous Thromboembolism in Women With Single or Multiple Thrombophilic Defects: Results From a Retrospective Family Cohort Study
29. Does the Potential for Development of Streptokinase Antibodies Change the Risk-Benefit Ratio in Older Patients?
30. An educational programme for peer review groups to improve treatment of chronic heart failure and diabetes mellitus type 2 in general practice
31. Neurohumoral and hemodynamic effects of ibopamine in a rat model of chronic myocardial infarction and heart failure
32. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death
33. Myocardial Infarction Enhances Progressive Renal Damage in an Experimental Model for Cardio-Renal Interaction
34. Clinical Trial in Nephrology at Hard End Point?
35. The effects of oral pretreatment with zofenopril, an angiotensin-converting enzyme inhibitor, on early reperfusion and subsequent electrophysiologic stability in the pig
36. New Strategies for the Conduct of Clinical Trials in Pediatric Pulmonary Arterial Hypertension: Outcome of a Multistakeholder Meeting With Patients, Academia, Industry, and Regulators, Held at the European Medicines Agency on Monday, June 12, 2017
37. Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome : Executive summary
38. Perceived barriers for treatment of chronic heart failure in general practice; are they affecting performance?
39. Comparison between New York Heart Association classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy
40. EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma
41. The European Medicines Agency's approval of new medicines for type 2 diabetes
42. Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases
43. EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma
44. Comment on the editorial by Turner et al. on assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al.
45. Risicocommunicatie over ernstige bijwerkingen: focus op Direct Healthcare Professional Communications
46. New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment
47. Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases
48. Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome: Executive summary
49. Abstracts of papers clinical pharmacological meeting
50. The European Medicines Agency's approval of proprotein convertase subtilisin/kexin type 9 inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.